The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Free Iona tests on NHS - good news for Premaitha: Buy

By HotStockRockets | Wednesday 2 November 2016

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

The Government has announced that as of 2018 it will offer free Non Invasive Prenatal Tests (NIPT) for Downs to women deemed to be at high risk - that is those over 38 years old. Right now it costs you £180 to have an NIPT test rather than an invasive one which has a 1% chance of killing your baby.

So there will clearly be a good take-up of the test and with Premaitha (NIPT) already having contracts with 50 NHS Hospitals it is well placed - assuming it beats Illumina in Court - to win a good share of the market.

The shares have motored ahead to 10p-10.5p on the news. that is still way down on what has been a dire share tip thanks entirely to Illumina's antics. But we expect more news of hard contract wins which will, at worst, support current forecasts to flow through soon and that this will drive a material re-rating over the next few months. The stance remains buy.

We are aware that the Iona test has raised some moral questions and these are discussed by Tom Winnifrith in an article HERE

To catch the next share tip from HotStockRockets out shortly and a real humdinger which came out on Friday afternoon  for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on NIPT


Comments are turned off for this article.

Site by Everywhen